Panagiotis Konstantinopoulos
Dana-Farber Cancer Institute · Dana-Farber Cancer Institute (DFCI) · Dana-Farber - Harvard Cancer Center LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Panagiotis Konstantinopoulos as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:26 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07832227 · Imlunestrant/Abemaciclib/Selinexor in Ovarian and EndometrialDana-Farber Cancer Institute · not yet recruiting · Low Grade Ovarian Serous Adenocarcinoma, Endometrial Cancer · principal investigator
- Ph2NCT06677190 · Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic OriginDana-Farber Cancer Institute · recruiting · Ovarian Cancer, Ovarian Carcinoma, Endometrial Cancer · principal investigator
- Ph2NCT06518564 · Avelumab and M1774 in ARID1A-mutated Endometrial CancerPanagiotis Konstantinopoulos, MD, PhD · active not recruiting · Endometrial Cancer, ARID1A Gene Mutation, Recurrent Endometrial Carcinoma · principal investigator
- Ph2NCT06366347 · ALPINE: Maintenance Letrozole/AbemaciclibDana-Farber Cancer Institute · recruiting · Endometrial Cancer, Recurrent Endometrial Cancer, TP53 · principal investigator
- Ph2NCT05548296 · A Phase 2 Study of ACR-368 in Endometrial AdenocarcinomaAcrivon Therapeutics · recruiting · Endometrial Adenocarcinoma · principal investigator
- Ph1NCT04024878 · NeoVax With Nivolumab in Patients With Ovarian CancerDana-Farber Cancer Institute · active not recruiting · Ovarian Cancer · principal investigator
- Ph2NCT02912572 · Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial CancerDana-Farber Cancer Institute · active not recruiting · Metastatic Endometrial Cancer · principal investigator
- Ph1NCT02627430 · Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast CancerNational Cancer Institute (NCI) · withdrawn · Adult Solid Neoplasm, Estrogen Receptor Negative, Fallopian Tube Serous Neoplasm · principal investigator
- Ph2NCT01307631 · Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial CancerNational Cancer Institute (NCI) · completed · Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma · principal investigator
- Ph2NCT00866723 · Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube CancerBeth Israel Deaconess Medical Center · terminated · Ovarian Cancer, Primary Peritoneal Serous Cancer, Fallopian Tube Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Combined ATR and P13k inhibition in uterine cancerP01CA269021 · NCI · DANA-FARBER CANCER INST · fiscal years 2024 to 2026 · $587,723 awarded in 2026Same name and institution; not confirmed by an ID
- Project 2: Combined personal neoantigen-targeting cancer vaccines with immune checkpoint blockade for ovarian cancerP50CA240243 · NCI · DANA-FARBER CANCER INST · fiscal years 2020 to 2024 · $392,202 awarded in 2024Grant number is on one of their registry trials
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Administrative CoreP30CA006516 · NCI · DANA-FARBER CANCER INST · PI Deborah J Goff · fiscal years 2018 to 2026Named on NCT02627430, NCT01307631
- Extension of the Dana Farber Harvard Cancer Center Consortium for the ETCTNUM1CA186709 · NCI · DANA-FARBER CANCER INST · PI KEITH T FLAHERTY, DONALD W. KUFE, Geoffrey I. Shapiro · fiscal years 2019 to 2026Named on NCT02627430, NCT01307631
- U01CA062490RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT01307631
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:26 UTC. The ranking covers the 200 most relevant of 34 PubMed records, and a shared surname and initials can bring in a namesake. All 34 on PubMed
- Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.Nat Commun · 2020249 citationsRCR 8.4
- Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.Lancet Oncol · 2019218 citationsRCR 7.4
- Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.JAMA Oncol · 2019202 citationsRCR 6.9
- Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.Lancet Oncol · 2020202 citationsRCR 7.7
- Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.J Clin Oncol · 2019187 citationsRCR 6.2
- 168 citationsRCR 4.9
- Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma.J Clin Oncol · 2021147 citationsRCR 7.1
- A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.J Clin Oncol · 202377 citationsRCR 6.4
- Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.Gynecol Oncol · 202075 citationsRCR 3.0
- Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer.J Immunother Cancer · 202069 citationsRCR 2.9